Paris, France and Camberley, UK – 16 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the proposed accounting treatment of the ongoing DHSC dispute on its unaudited H1 2021 interim results for the six months ended 30 June 2021. The interim results are expected to be announced
Visit PageCategory: Products
AGM voting
Paris, France and Camberley, UK – 13 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as a closed meeting at 2pm CEST/1pm BST on Wednesday, 29 September 2021. As usual, and in accordance with French corporate law, the AGM comprises
Visit PageNotice of AGM
Paris, France and Camberley, UK – 20 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM) will be held as a closed meeting at 2pm CEST/1pm BST on Wednesday, 29 September 2021. The AGM comprises both ordinary and extraordinary general meetings. http://novacyt.com/wp-content/uploads/2021/08/Novacyt-Notice-of-AGM-Aug-2021.pdf
Visit PageHalf Year Update
Investor meeting at 13:00 BST / 14:00 CEST Paris, France and Camberley, UK – 18 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces a half year update in advance of its investor meeting today. http://novacyt.com/wp-content/uploads/2021/08/Novacyt-half-year-update.pdf
Visit PageNotice of investor meeting
Paris, France and Camberley, UK – 5 August 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces that it will hold an investor meeting on Wednesday, 18 August 2021, at 13:00 BST / 14:00 CEST. http://novacyt.com/wp-content/uploads/2021/08/Novacyt-Notice-of-Investor-meeting-.pdf
Visit PageDavid Allmond announced as CEO following decision by Graham Mullis to retire
Paris, France and Camberley, UK – 29 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a leading international specialist in clinical diagnostics, announces the appointment of David Allmond as CEO and a member of the Board of Directors effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he
Visit PageDirector/PDMR Shareholding
Paris, France and Camberley, UK – 06 July 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 05 July 2021, Guillermo Raimondo, Chief Commercial Officer of the Company, acquired 10,000 ordinary shares of €1/15 each in the Company at a price of
Visit PageExpansion of PathFlow® COVID-19 lateral flow test portfolio
Paris, France and Camberley, UK – 29 June 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral flow tests (LFTs) to strengthen the Company’s COVID-19 portfolio and to pursue significant new market opportunities, especially in point-of-care (POC) settings. The Company will initially
Visit PagePublication of Annual Report
Paris, France and Camberley, UK – 29 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2020 has been published and uploaded to the Company’s website. The Annual Report has been posted
Visit PageFull year 2020 results and update on growth strategy
Transformational performance in 2020Continued strong demand for COVID-19 testing in 2021Strategy to deliver long-term growth through test, instrument, and geographic expansion in key areas, supplemented by M&A http://novacyt.com/wp-content/uploads/2021/06/Novacyt-full-year-2020-results-Final-ENGLISH.pdf
Visit Page